Now available TEVIMBRA®

TEVIMBRA® (tislelizumab-jsgr) is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.

Please see full prescribing information here.